Next generation probiotics (NGP) includes the unconventional probiotic microbes and genetically modified micro-organisms, under a regulatory framework. The concept overlaps with the emerging concept of live biotherapeutics (LBP). Advances in synthetic biology, genome engineering, and DNA sequencing and synthesis have been enabled scientists to design and develop probiotics with increased efficiency. Some of the projected examples of candidate species are Akkermansia sp., Bacteriodes sp., Faecalibacterium sp., etc. The development and commercialization of LBP is bit challenging and the factory processes include identification of LBP, characterization, production and the clinical evaluation. The production of conventional probiotics being a challenge in the industry, LBP opens a way forward to the purpose. A complete characterization and description of each LBP strain intended to be used is essential for its approval. But the experimental research phase of LBP promising its wide array of applications in the areas of drug administration, vaccine delivery, immunomodulation, cancer therapy etc., apart from its probiotic usage. In this perspective, future research may direct towards the concerns like bio containment of these engineered probiotics - interactions between the synthetic LBPs and commensal microbes.